MedTrace Logo

Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

NCT04141501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-09-21

No results posted yet for this study

Summary

Effects of serotonin 2A/1A receptor stimulation by psilocybin on alcohol addicted patients: a randomized double-blind placebo-controlled study

Conditions

Interventions

DRUG

Psilocybin

single dose of psilocybin (25mg). orally in form of a capsule

DRUG

Placebo oral capsule

single dose of mannitol (100%)

Sponsors & Collaborators

  • Schweizerischer Nationalfonds

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Katrin Preller, Dr. · Psychiatric University Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2023-03-14
Completion
2023-09-14

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141501 on ClinicalTrials.gov